

FOR IMMEDIATE RELEASE

Bio Vitos takes the next step towards EU funding – wholly owned FERROVITOS AB receives PIC number

LONDON / STOCKHOLM — 26 October 2026 — Bio Vitos Ltd ("Bio Vitos" or the "Company") announces that its wholly owned Swedish subsidiary FERROVITOS AB has received a PIC number in the EU Funding & Tenders Portal. The registration is an important administrative step in the group's pursuit of European funding for research, innovation and commercial development. Bio Vitos intends to apply for funding under the EIC Accelerator through FERROVITOS.

AT A GLANCE

PIC

FERROVITOS AB
registered in the EU
Funding & Tenders Portal

EIC

planned application to the
EIC Accelerator

€2.5 M

maximum grant under the
2026 terms, up to 70% of
costs

€1–10 M

possible equity
investment via EIC Fund

— What does a PIC number mean?

PIC stands for *Participant Identification Code* and is an organisation's unique identification number in the EU's application system. The number is used for applications and in contacts with EU funding bodies. Eligibility for each programme is assessed separately.

With the registration, FERROVITOS AB – established in October 2026 as the group's Swedish research and development company – now has the formal identity required to submit applications to EU research and innovation programmes.



"With FERROVITOS we have established a Swedish research platform within the EU. The PIC registration takes us another step forward in financing our continued development. Our ambition is to combine clinical research, academic collaboration and European innovation funding to develop accessible solutions in iron health."

— Cato Crogh, Chairman of the Board

— EIC Accelerator – support for breakthrough innovation

The EIC Accelerator is a funding programme within the EU's Horizon Europe. It targets innovative start-ups and small and medium-sized enterprises with strong commercial potential, international growth ambitions and innovations that can create new markets or transform existing ones. The programme offers both funding and support through coaching, investor contacts and partnerships.

Under the 2026 terms, funding can normally include:

Grant up to €2.5 M Covers a maximum of 70% of eligible project costs.	Equity investment €1–10 M For example through shares or convertible instruments.	Blended finance Grant + investment The investment component is equity financing and is separate from the grant.
---	--	---

The amount and form of funding to apply for will be set by the project's scope, stage of development and capital needs.

— Continued development of the research programme

Bio Vitos' research programme comprises several clinical studies focused on iron deficiency and iron absorption:

FE-MININ Clinical study of iron treatment in women. The participant phase has been completed through Linköping University.	MAXFERMAN Planned clinical study of 80 men aged 25–55, with planned start on 15 January 2027.	FE-MINI Planned study focused on children with iron deficiency.
--	---	---

FERROVITOS will serve as the group's Swedish base for continued research and development. Ahead of an EIC application, the project will be assessed against the programme's requirements for innovation, technical and commercial maturity and SME status, given the group's ownership structure.

— Next steps

01

Assess which project best fits the EIC Accelerator's criteria.

02

Determine the amount and form of funding based on the project's capital needs.

03

Prepare the application and deepen collaboration with universities and European partners.

The PIC registration does not mean that funding has been granted. An application will undergo the programme's standard eligibility check and competitive evaluation. No grants or investments are guaranteed.

— About FERROVITOS AB

FERROVITOS AB is a wholly owned Swedish subsidiary of Bio Vitos Ltd focused on R&D in iron deficiency, iron absorption and future iron treatments. It runs the group's Swedish research activities and applications for national and European funding.

#

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements regarding, among other things, the possibility of obtaining EU funding, programme terms, eligibility and evaluation, and the timing and conduct of clinical studies. Actual outcomes may differ materially. The Company undertakes no obligation to update these statements.

ABOUT BIO VITOS LTD

Bio Vitos Ltd develops oral iron products based on ferrous succinate and runs a research programme focused on iron deficiency. FERROVITOS AB is the Company's wholly owned Swedish subsidiary focused on research and development.

CONTACT

Cato Crogh
Chairman of the Board, Bio Vitos Ltd
E-mail: cato@payzinos.com
Web: www.biovitos.com